Ioversol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ioversol: From Radiographic Contrast Imaging to Osteoarthritis Susceptibility
One-Sentence Summary
Ioversol is an iodinated, non-ionic radiographic contrast agent used to enhance imaging. The TxGNN model predicts it may be relevant to osteoarthritis susceptibility, but no clinical trials and no publications directly support this prediction. It is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data (iodinated contrast agent for diagnostic imaging) |
| Predicted New Indication | Osteoarthritis susceptibility |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ioversol is an iodinated, non-ionic contrast agent. It works by attenuating X-rays during imaging, not by acting on disease biology.
No mechanistic link to osteoarthritis susceptibility was identified. Susceptibility to osteoarthritis is a genetic and predisposition concept, and ioversol has no known pharmacologic action on it. The high TxGNN score reflects a graph-based computational association only.
Other top-ranked predictions show the same pattern. Osteoarthritis, rheumatoid arthritis, several rare skeletal dysplasias (brachyolmia, acromesomelic dysplasia), hemoglobinopathy, myosclerosis and alopecia all have scores above 99%. None has a plausible mechanism, and these scores are likely artifacts of the graph structure.
For osteoarthritis (rank 2), one publication exists (PMID 38102013). It studies genicular artery embolization with an ethiodized oil-based agent, not ioversol. Ioversol's only plausible role would be as an imaging aid for such a procedure, which is not a therapeutic effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature directly supports the top prediction (osteoarthritis susceptibility). The only indirectly related publication, found under the osteoarthritis prediction, is listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38102013 | 2024 | Single-arm clinical trial | Diagnostic and Interventional Imaging | LipioJoint-1: safety and efficacy of transient genicular artery embolization using an ethiodized oil-based emulsion for knee osteoarthritis. It does not study ioversol. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07748P | OPTIRAY 350 INJECTION 74% | Injection | Not available in licence record |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interactions in total. Many of the listed ones are rated Major. Main examples:
- Metformin (Major)
- Amphotericin B, including lipid complex, cholesteryl sulfate and liposomal forms (Major)
- Aminoglycosides and related antibiotics: kanamycin, neomycin, streptomycin, and also vancomycin and polymyxin B (Major)
- Aminosalicylates: mesalazine, balsalazide, olsalazine, sulfasalazine (Major)
- Mannitol (Moderate)
Please refer to the package insert for key warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no trials, no supporting literature, and no plausible mechanism linking a diagnostic contrast agent to osteoarthritis susceptibility. The one related publication does not involve ioversol.
To proceed, the following is needed:
- Mechanism of action data for ioversol, and any biological rationale for the predicted indication
- Package insert warnings and contraindications from the Singapore regulator
- Approved indication text for the Singapore licence
- Any direct preclinical or clinical study of ioversol in osteoarthritis
- Confirmation of route and formulation compatibility (ioversol is available only as an injection)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.